Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of tucatinib + trastuzumab with optional fulvestrant in HER2-altered advanced solid tumors
NL-OMON51882Phase 2Not yet recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucatinib, trastuzumab and fulvestrant in Nonhematologic neoplasms, breast cancer, biliary cancer and 3 more (2 arms), sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoints: Antitumor activity by investigator assessment per RECIST v1.1 and Safety and tolerability. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmsbreast cancerbiliary cancernon-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON51882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51882.